Samuel Ademola Adegoke1, Rejane de Souza Macedo-Campos2, Josefina Aparecida Pellegrini Braga3, Maria Stella Figueiredo4, Gisele Sampaio Silva5. 1. Haematology and Blood Transfusion Division, Universidade Federal de São Paulo, São Paulo, Brazil; Department of Pediatrics and Child Health, Obafemi Awolowo University, Ile-Ife, Nigeria. Electronic address: adegoke2samade@yahoo.com. 2. Department of Neurology and Neurosurgery, Universidade Federal de São Paulo, São Paulo, Brazil. 3. Department of Pediatrics, Universidade Federal de São Paulo, São Paulo, Brazil. 4. Haematology and Blood Transfusion Division, Universidade Federal de São Paulo, São Paulo, Brazil. 5. Department of Neurology and Neurosurgery, Universidade Federal de São Paulo, São Paulo, Brazil; Programa Integrado de Neurologia, Hospital Israelita Albert Einstein, São Paulo, Brazil.
Abstract
BACKGROUND AND OBJECTIVES: Hydroxyurea (HU) was recently described as a substitute for chronic transfusion for children with sickle cell disease (SCD) and abnormal transcranial Doppler (TCD) velocities who have received at least 1 year of transfusions. However, the role of HU in reverting elevated TCD velocities in patients not treated with transfusion is still debatable. The objective of the study was to examine whether HU influences the progression of TCD velocities in children with SCD. PATIENTS AND METHODS: Children with SCD with at least 2 TCDs not less than 6 months apart were evaluated over 51 months. Time-averaged maximum mean (TAMM) velocities for the initial and the last transcranial Doppler examinations were noted and differences compared between HU and HU-naive groups. RESULTS: Overall, 68.8% of the HU-group with elevated TCD velocities compared with 40.0% of the HU-naive experienced TCD reversal (P = .047). A higher proportion of the HU-naive group, 7 (14.3%) versus 9.8% of the HU group experienced TCD conversion. Those with initial conditional velocities in the HU-group experienced a significant reduction in TAMM velocities (from 176.8 ± 5.3 to 162.7 ± 13.9 cm/s, difference of 14.1 cm/s; P = .001) unlike those in the HU-naive group (176.3 ± 5.3 to 170.0 ± 18.6 cm/s, difference of 6.3 cm/s; P = .148). The change in the TAMM velocities was also significantly higher among the HU-group (14.1 ± 12.4 cm/s versus 6.3 ± 18.5 cm/s, P = .015). CONCLUSION: Our data suggest a beneficial role of HU in TCD velocity reduction in patients not treated with chronic transfusions, particularly among those with initial conditional TCD velocities.
BACKGROUND AND OBJECTIVES:Hydroxyurea (HU) was recently described as a substitute for chronic transfusion for children with sickle cell disease (SCD) and abnormal transcranial Doppler (TCD) velocities who have received at least 1 year of transfusions. However, the role of HU in reverting elevated TCD velocities in patients not treated with transfusion is still debatable. The objective of the study was to examine whether HU influences the progression of TCD velocities in children with SCD. PATIENTS AND METHODS: Children with SCD with at least 2 TCDs not less than 6 months apart were evaluated over 51 months. Time-averaged maximum mean (TAMM) velocities for the initial and the last transcranial Doppler examinations were noted and differences compared between HU and HU-naive groups. RESULTS: Overall, 68.8% of the HU-group with elevated TCD velocities compared with 40.0% of the HU-naive experienced TCD reversal (P = .047). A higher proportion of the HU-naive group, 7 (14.3%) versus 9.8% of the HU group experienced TCD conversion. Those with initial conditional velocities in the HU-group experienced a significant reduction in TAMM velocities (from 176.8 ± 5.3 to 162.7 ± 13.9 cm/s, difference of 14.1 cm/s; P = .001) unlike those in the HU-naive group (176.3 ± 5.3 to 170.0 ± 18.6 cm/s, difference of 6.3 cm/s; P = .148). The change in the TAMM velocities was also significantly higher among the HU-group (14.1 ± 12.4 cm/s versus 6.3 ± 18.5 cm/s, P = .015). CONCLUSION: Our data suggest a beneficial role of HU in TCD velocity reduction in patients not treated with chronic transfusions, particularly among those with initial conditional TCD velocities.
Authors: Shehu U Abdullahi; Binta J Wudil; Halima Bello-Manga; Aisha B Musa; Safiya Gambo; Najibah A Galadanci; Hauwa Aminu; Aliyu Tijjani Gaya; Surayya Sanusi; Musa A Tabari; Aisha Galadanci; Awwal Borodo; Muhammed S Abba; Abdu H Dambatta; Lawal Haliru; Awwal Gambo; Holly Cassell; Mark Rodeghier; Djamila L Ghafuri; Brittany V Covert Greene; Kathleen Neville; Adetola A Kassim; Fenella Kirkham; Edwin Trevathan; Lori C Jordan; Muktar H Aliyu; Michael R DeBaun Journal: Pediatr Hematol Oncol Date: 2020-11-25 Impact factor: 1.969
Authors: Kristine Karkoska; Charles T Quinn; Omar Niss; Amanda Pfeiffer; Min Dong; Alexander A Vinks; Patrick T McGann Journal: Am J Hematol Date: 2021-02-19 Impact factor: 10.047
Authors: Nirmish Shah; Menaka Bhor; Lin Xie; Rashid Halloway; Steve Arcona; Jincy Paulose; Huseyin Yuce Journal: Health Qual Life Outcomes Date: 2019-10-16 Impact factor: 3.186
Authors: Melanie E Fields; Kristin P Guilliams; Dustin Ragan; Michael M Binkley; Amy Mirro; Slim Fellah; Monica L Hulbert; Morey Blinder; Cihat Eldeniz; Katie Vo; Joshua S Shimony; Yasheng Chen; Robert C McKinstry; Hongyu An; Jin-Moo Lee; Andria L Ford Journal: Blood Date: 2019-03-11 Impact factor: 22.113
Authors: M R DeBaun; L C Jordan; A A King; J Schatz; E Vichinsky; C K Fox; R C McKinstry; P Telfer; M A Kraut; L Daraz; F J Kirkham; M H Murad Journal: Blood Adv Date: 2020-04-28
Authors: Andrew M Heitzer; Jennifer Longoria; Victoria Okhomina; Winfred C Wang; Darcy Raches; Brian Potter; Lisa M Jacola; Jerlym Porter; Jane E Schreiber; Allison A King; Guolian Kang; Jane S Hankins Journal: Br J Haematol Date: 2021-07-16 Impact factor: 8.615